Raphael Stevens

[The stream is slated to start at 10:00 a.m. ET. Please refresh the page if you do not see a player above at that time.]Officials from the National Institutes of Health testify before Congress Tuesday on the agency’s annual budget as the nation battles the Covid-19 pandemic.Witnesses include White House chief medical advisor Dr. Anthony Fauci, who also runs the National Institute of Allergy and Infectious Diseases within NIH, as well as directors from the nation’s top medical institutions.NIH Director Dr. Francis S. Collins is also testifying before the House Committee on Appropriations and the Subcommittee on Labor, Health and Human Services along with Dr. Diana W. Bianchi, the Director of Eunice Kennedy Shriver National Institute of Child Health and Human Development.Other witnesses include Dr. Gary H. Gibbons, the Director of the National Heart, Lung, and Blood Institute, Dr. Norman E. Sharpless, the Director of the National Cancer Institute, and Dr. Nora D. Volkow, the Director of the National Institute on Drug Abuse.Read CNBC’s live updates to see the latest news on the Covid-19 outbreak.Correction: This article was updated to correct the spelling of Dr. Norman Sharpless’ name. More

Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), testifies before a Senate Health, Education, Labor, and Pensions hearing to examine an update from Federal officials on efforts to combat COVID-19 in the Dirksen Senate Office Building on May 11, 2021 in Washington, DC.Jim Lo Scalzo | Getty ImagesWhite House chief medical advisor Dr. Anthony Fauci said Tuesday that the U.S. can still achieve its goal of ending the HIV epidemic by 2030 despite the ongoing Covid-19 pandemic, which saw testing sites for other diseases temporarily shut down and medical personnel being reassigned.Fauci, who oversees research to prevent, diagnose and treat established infectious diseases at the National Institute of Allergy and Infectious Diseases, told a House committee that the nation has not gone “backward” in the fight against HIV. Efforts to combat the pandemic have supplanted other medical research, putting some drugs under development on hold as pharmaceutical companies diverted research and resources to Covid-19 treatments and vaccines.”Obviously, when you shut down society, the accessibility for testing and the chain for drug availability can be disrupted the same way everything is disrupted, including vaccinations for children,” he said during a hearing by the House Committee on Appropriations and the Subcommittee on Labor, Health and Human Services.Roughly 1.2 million people in the United States are currently living with HIV and about 14% of them don’t know they have it, according to government data. Roughly 38,000 Americans become infected with the virus each year, according to the U.S. data.In 2019, the Trump administration announced a pledge to end the HIV epidemic in the U.S. by 2030, a goal that public health advocates have cheered and sought for years. However, some advocates later expressed concerns that the pandemic’s impact on medical care would lead to a rise in new HIV infections.Fauci, who has advised at least seven U.S. presidents on HIV and other health issues, on Tuesday mentioned a number of advances in HIV care.People at risk of HIV can now take prevention medication, also known as pre-exposure prophylaxis or PrEP, he said. PrEP can reduce the risk of infection from sex by about 99% in people who take the drug daily, according to the Centers for Disease Control and Prevention.”The PrEP, pre-exposure prophylaxis, is an important ingredient in our attempt over 10 years from 2020 to 2030 to end the epidemic in the United States,” he said. “I believe, notwithstanding Covid-19, that we will achieve that goal.” More

NASA astronaut Peggy Whitson working onboard the International Space Station in August 2017.Jack Fischer / NASAAxiom Space on Tuesday announced that retired NASA astronaut Peggy Whitson and auto racer John Shoffner will lead the company’s second private spaceflight to the International Space Station, tentatively scheduled for the second half of 2022.The pair will fly Axiom’s Ax-2 mission for an eight-day stay on the ISS, with Whitson as the commander and Shoffner as the pilot. Currently Axiom is working toward its Ax-1 mission, which is scheduled to launch in January 2022 using a SpaceX rocket and capsule to reach the ISS.Whitson left NASA in 2018 and began consulting for Axiom a little over a year ago. She set multiple historic firsts while with the space agency, including the U.S. record for cumulative time spent in space at 665 days, the first female commander of the ISS in 2007, and the first female and non-military chief of NASA’s astronaut office.She told CNBC that she looks forward to returning to orbit, especially since her experience helps better inform what Axiom is working toward as a private company.”One thing that an astronaut always tries to figure out is: ‘How do I get back?'” Whitson said.She added that that space is now on “a precipice of change,” going from the realm of government organizations to one of the private sector for companies like Axiom.”I think commercial space operations are required for the infrastructure to be built in low Earth orbit,” Whitson said.Peggy Whitson, left, and John ShoffnerAxiom SpaceShoffner, on the other hand, joins Ax-2 without prior spaceflight experience – but brings years of experience in motorsports and piloting in air shows, fused with a lifelong dream of becoming an astronaut. He says he first heard of Axiom about a year and a half ago and describes himself as a “huge space fan.””In my first early meetings with Axiom, I was introduced to Peggy Whitson – who is a revered NASA astronaut,” Shoffner said. “Having a chance to fly with her is going to be absolutely incredible.”Before forming his motorsports team J2-Racing with his wife Janine, Shoffner was a businessman. He worked his way up through Kentucky-based telecommunications manufacturer Dura-Line over a 21-year career, until he retired as president in 1996.”We’re very excited to be flying together, and I am really thrilled because John seems just like an incredibly high-caliber person … he’s got the right stuff to do it,” Whitson said. “I think he has the right interpersonal skills that will make it fun to fly with – and I’ve learned over my experiences in space that is not when you fly, but who you fly with that’s most important.”Crew Dragon spacecraft “Resilience” approaches the International Space Station in orbit.NASAWhile the Ax-1 mission will utilize SpaceX’s Crew Dragon capsule and Falcon 9 rocket, the company said that the launch vehicle and spacecraft for Ax-2 has not yet been finalized. Axiom aims to fly these private missions to the ISS every six to seven months, but that is subject to space station traffic and windows in NASA’s schedule for private flights.Whitson and Shoffner have been training alongside the Ax-1 crew, in the meantime, as the pair are serving as back-ups for that mission’s commander Michael López-Alegría and pilot Larry Connor.Axiom declined to disclose financial details about the Ax-2 mission’s expected total cost. A SpaceX crew launch costs NASA about $55 million per seat, so the price for these private missions is expected to be similarly high.In addition to training for Ax-2, Whitson and Shoffner are working with California-based biotechnology company 10x Genomics to perform research in orbit on single-cell genomic methods.”Their products are used by all the top 100 research facilities around the world, researchers in orbit have been looking for the same capabilities,” Shoffner said of 10x Genomics.The company’s research will look to help answer questions such as how humans live in space long-term. Whitson noted that the the Ax-2 mission’s shorter duration will get the research back to 10x Genomics faster.”Accessibility is one of the advantages of flying it with us, as it can get to orbit sooner and be tested sooner,” Whitson said.The view from SpaceX’s Crew Dragon spacecraft Endeavour of the International Space Station, as well as the company’s Crew Dragon spacecraft Resilience, as the capsule approached to dock on April 24, 2021.NASA TVAxiom plans to later announce two more members of the Ax-2 mission. One of those crew members is expected to be from a Discovery adventure TV show called “Who Wants To Be An Astronaut?” that would launch the winning contestant on the mission.Become a smarter investor with CNBC Pro.Get stock picks, analyst calls, exclusive interviews and access to CNBC TV. Sign up to start a free trial today. More

In this articleAMZNPent-up consumer demand and a surge in online shopping due to the pandemic could make Amazon Prime Day even more popular.Which says a lot, considering it’s one of the most anticipated shopping events of the year.Prime Day, which is usually slated for July, typically includes discounts on more than 1 million items, including intermittent “Lightning Deals,” for Prime members. This year, the online retail giant is expected to kick off its annual two-day shopping event in June. Here’s how to make the most of the upcoming sale.More from Personal Finance:The government is still sending $1,400 stimulus checksPrices are going up — here’s what inflation means to youThe pandemic drove these Americans into early retirement”I always expect there to be some great deal on one item that everyone buys,” said Julie Ramhold, a consumer analyst at DealNews.com, of the two-day shopping event.  In the past, some of the most popular items have included the Instant Pot, Echo Dot and, of course, the Amazon coat.Last year, amid the coronavirus outbreak, many of the deals were geared toward staying in. “This year, we’ve swung back in the other direction,” Ramhold said.Expect deep discounts on items related to entertaining and traveling, such as backyard games, TVs, headphones, exercise gear and Amazon devices like the Kindle, Fire TV streamer or Ring video doorbell.In order to take advantage of Prime Day deals, you must be an Amazon Prime member. You can sign up for a month-to-month membership for about $13 or pay $119 for the year. For deal hunters, note that membership also includes free music, movies and e-books, as well as discounts on groceries at Whole Foods.Then, download the Amazon app, scroll through upcoming deals and mark the items you are interested in as “watching,” Ramhold advised. You’ll receive a notification when the price drops.When a deal is live, add the item to your cart immediately. Some Lightning Deals can sell out quickly, Ramhold said. Once it is in your cart, you’ll have 15 minutes to decide whether to complete the purchase.If there is a specific product that you are set on and you don’t see it in upcoming sales, you can create a wish list and Amazon will alert you if it does become part of a Prime Day deal.To capitalize on your savings even more, consider using a credit card with rewards or cash back. As vaccination rates increase and restrictions ease, plans for post-pandemic sprees — or so-called revenge shopping — are already underway, according to a recent spending survey by LendingTree.Nearly half of all consumers said they are so eager to shop that it’s at least somewhat likely they’ll go into debt this summer, the survey of more than 2,100 Americans found.”This feel-better situation will likely translate into higher levels of household spending,” according to Jack Kleinhenz, chief economist at the National Retail Federation. “Today’s year-over-year numbers are off the charts in some categories,” he added, particularly clothing, furniture and sporting goods.”The economy and consumer spending have proven to be much more resilient than many feared a year ago,” Kleinhenz said.Subscribe to CNBC on YouTube. More

In the ninth annual Disruptor 50 list, CNBC highlights the private companies leading out of the pandemic with business models and growth rates aligned with a rapid pace of technological change. Investors have taken notice that the companies on the 2021 Disruptor 50 list have become critical players in fundamental economic and consumer transformations. A majority of the CNBC Disruptor 50 are already billion-dollar businesses. Thirty-four disruptors are unicorns that have already reached or passed (in some cases far surpassed) the $1 billion valuation mark — 10 of the companies on this year’s list are worth at least $10 billion. The 50 companies selected using the proprietary Disruptor 50 methodology have raised over $72 billion in venture capital, according to PitchBook, at an implied Disruptor 50 valuation of more than $388 billion. While technologies including AI, 5G, cloud computing and the Internet of Things are key to many companies making the 2021 Disruptor 50 list, the sectors they are upending are widespread, from financial services to health care, biotech, education, food, media, agriculture and transportation.1RobinhoodWall Street’s frenemy2StripeThe GDP of the Internet3DiscordThe Internet chat room, re-imagined4SentinelOneA SolarWinds saving grace5Didi ChuxingYour $100 billion IPO is on the way6BrexGiving credit to the start-up economy7MarqetaPlaying their cards right8ChimeSoftware as a bank9TytoCareUrgent care delivered virtually10ElevateBioBuilding a deep lab bench11K HealthThe health care app will see you now12ConvoyFreight’s neural network13Checkout.comTransactional relationships14Indigo AgTop soil15SnykSniffing out open-source flaws16TempusInforming the precision clinician17Lineage LogisticsCold comfort18GojekSoutheast Asia’s super-app19CLEARKeep the line moving20TALAThe underserved deserve credit21FlutterwaveHelping Africa’s small business soar22ThrasioTransforming the Amazon economy23Relativity SpaceEngineering an interplanetary future24Impossible FoodsBeyond possible25AMP RoboticsRobots recycle better26NeteeraA sixth sense in medicine27Cockroach LabsDeep inside enterprise cloud data28Cityblock HealthBecause everyone deserves good health care29UdacityGraduating a new generation of skilled labor30ApeelGood preservatives31Sight DiagnosticsSee the whole picture in two drops of blood32CybereasonFighting the dark side33ClubhouseThe new sound of social34Sila NanotechnologiesMaking EV batteries better is no small thing35BestowDigital transformation comes to life (insurance)36GopuffWhen you need stuff ASAP37DatabricksThe next Snowflake?38RippleMaking waves in crypto regulation39PlaidThe gateway to Venmo, Robinhood, Coinbase40NubankLatin America’s big bank challenger41FlexportSupply chain economics42Flock FreightCarbon-smart truckloads43Eat JustThe egg and the chicken44MovandiMaking 5G a broader reality45FootprintJust three words for you: No more plastic46AirtableCode for non-coders47BlocPowerFighting climate change block-by-block48PatreonHow the creative class gets paid49Guild EducationEducation as a benefit50HealNew ideas in home-based health care More

In this articleUNHA United Airlines Holdings Inc. employee helps a traveler at a ticket counter for Hawaii at San Francisco International Airport (SFO) in San Francisco, California, U.S., on Thursday, Oct. 15, 2020.David Paul Morris | Bloomberg | Getty ImagesSummer vacations are getting more and more expensive as travelers return from the long pandemic lull.United Airlines said Tuesday that yields on domestic leisure tickets purchased this month topped 2019 levels and said the trend would continue through summer, echoing similar comments from Southwest Airlines last week.United said total revenue per available seat mile, a gauge of how much revenue airlines are bringing in compared with its capacity, would be down 12% for the second quarter from previous guidance of about a 20% decline. Weak business travel demand is weighing on yields overall, though those are close to 2019 levels, United said.Zoom In IconArrows pointing outwardsUnited expects to get to post positive adjusted earnings before interest, taxes, depreciation and amortization in the third quarter and narrower losses for the second quarter.U.S. airport screenings have returned to pre-pandemic volumes but are still low for this time of year. On Monday, the Transportation Security Administration said it screened 1.86 million people compared with 2.1 million on the same date in 2019 and just 267,451 last year.United shares were up 3.2% in premarket trading. More

In this articleMRNAA young man receives his Covid-19 vaccination at a vaccination clinic. People receive the Moderna vaccine in Milford, Pennsylvania.Preston Ehrler | LightRocket | Getty ImagesModerna said Tuesday its Covid-19 vaccine was 100% effective in a study of adolescents ages 12 to 17, making it the second shot behind Pfizer’s to demonstrate high efficacy in younger age groups.The company said it plans to ask the Food and Drug Administration to expand the emergency use of its Covid vaccine for teens early next month. If approved, it would likely dramatically expand the number of shots available to middle and high school students ahead of the next school year. Pfizer and German partner BioNTech were cleared to use their vaccine for 12- to 15-year-olds earlier this month.”We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents,” Moderna CEO Stephane Bancel said in a press release. “We remain committed to doing our part to help end the COVID-19 pandemic.”The two-dose vaccine, which is given four weeks apart, is already authorized for adults.The phase 2/3 study the company is citing Tuesday included more than 3,700 adolescents. No cases of Covid were observed in participants who received two doses of the vaccine, while four cases were observed in the placebo group, according to the company.No significant safety concerns have been identified, and side effects generally are consistent with those seen in an earlier trial of adults, the company said. The most common side effects after the second dose were headache, fatigue, muscle pain and chills, Moderna said.The new data comes less than three weeks after the company disclosed in an earnings report that early data showed the shot was 96% effective at protecting against Covid in teens ages 12 to 17. That data was based on those who received at least one dose of the vaccine.The company said Tuesday the shot was shown in the trial to be 93% effective after one dose. Because children are less likely to get seriously ill, Moderna used the Centers for Disease Control and Prevention’s definition of Covid-19 to calculate that figure. It requires only one symptom and a positive Covid test.U.S. regulators are expected to grant Moderna’s request for use in teens. The approval process could take about a month, just in time for some summer activities and fall classes if Moderna submits the data by early June. Pfizer and BioNTech requested expanded use of their shot in adolescents on April 9, for example, and were authorized by the FDA on May 10.Vaccinating children is seen as crucial to ending the pandemic. The nation is unlikely to achieve herd immunity — when enough people in a given community have antibodies against a specific disease — until children can get vaccinated, health officials and experts say.Children make up around 20% of the total U.S. population, according to government data. Some 70% to 85% of the U.S. population needs to be vaccinated against Covid to achieve herd immunity, medical experts say, and some adults may refuse to get the shots. Though more experts now say herd immunity is looking increasingly unlikely as variants spread.Vaccinating kids may also hasten the return of in-person learning and greenlight after-school extracurricular activities such as sports, art and other in-person activities, health experts say. More